Tag: chronic plaque psoriasis market research

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Plaque Psoriasis Market?

Rising instances of immune system dysfunction are anticipated to boost the expansion of the chronic plaque psoriasis market. This dysfunction refers to a condition in which the immune system’s efficiency declines, resulting in a higher propensity to infections, autoimmune diseases, and cancer. The mushrooming instances of immune system dysfunction can be attributed to genetic predispositions, environmental influences, malnutrition, prolonged stress, as well as increasing incidence of autoimmune disorders and infections like HIV. For the management of immune system dysfunction, treatment for chronic plaque psoriasis is crucial because the immune system erroneously provokes an excessive proliferation of skin cells, resulting in inflammation and plaque formation. For example, in December 2022, the U.S-based nonprofit organization, National Psoriasis Foundation, revealed that psoriasis affects over 8 million Americans. On a global scale, the ailment affects 125 million individuals, constituting about 2 to 3% of the overall population. Thus, the escalating instances of immune system dysfunction are fueling the growth of the chronic plaque psoriasis market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

How Has the Chronic Plaque Psoriasis Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

There has been a substantial expansion in the size of the chronic plaque psoriasis market in the past few years. Its growth is projected to increase from $20.79 billion in 2024 to $22.32 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%. Causative factors for the growth during the historic period include heightened psoriasis prevalence, an uptick in co-morbidity instances, favorable reimbursement policies, an increase in alcohol and smoking intake, and the advent of telemedicine.

Sturdy growth is predicted for the chronic plaque psoriasis market over the forthcoming years, with a projected increase to $29.33 billion by 2029, indicating a compound annual growth rate (CAGR) of 7.1%. This upward trend during the forecast period is due to factors such as a rise or fall in the global incidence of cpp, an upsurge in autoimmune disorders, enhanced healthcare budgets, an aging populace and heightened demand for impactful treatments. The period of forecast will also witness major trends like evolution in biologic treatments, oral small molecule inhibitors, incorporation of digital health, personalized medication, and the introduction of biosimilars.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

What Are the Key Market Innovations in theChronic Plaque Psoriasis Market Over the Coming Years?

Prominent enterprises in the chronic plaque psoriasis sector are intensifying their efforts to create ground-breaking treatments, such as IL-17A and IL-17F inhibitors, in order to upgrade the management of chronic plaque psoriasis. These inhibitors are specialized biologic remedies designed to inhibit interleukin-17A and interleukin-17F, pro-inflammatory cytokines that play a vital role in the immune responsive process, with the aim to lower inflammatory conditions in autoimmune disorders such as chronic plaque psoriasis. In a case in point, UCB S.A., a biopharmaceutical firm from Belgium, in October 2023, revealed that the U.S. Food and Drug Administration (FDA) had sanctioned BIMZELX (bimekizumab-bkzx) for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bimekizumab is the inaugural medication exclusively developed for psoriasis to target and restrain interleukin 17A (IL-17A) and interleukin 17F (IL-17F), which are two critical cytokines driving inflammatory reactions. Its endorsement came on the strength of data gathered from three Phase 3 multicenter studies—BE READY, BE VIVID, and BE SURE— that evaluated the safety and effectiveness of the medication in 1,480 patients suffering from moderate to severe plaque psoriasis.

Who Are the Top Companies Driving Innovation and Growth in theChronic Plaque Psoriasis Market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Key Market Segments Comprise the Chronic Plaque Psoriasis Market and Drive Its Revenue Growth?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Which Regions Are Emerging as Leaders in the Chronic Plaque Psoriasis Market?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2025, By The Business Research Company:

Psoriasis Global Market Report 2025

https://thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Global G-CSF (Granulocyte Colony Stimulating Factors) Opportunities And Strategies Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the chronic plaque psoriasis market right now?

Recent years have witnessed a robust growth in the size of the chronic plaque psoriasis market. The market, which is predicted to increase from $20.79 billion in 2024 to $22.32 billion in 2025, is expected to experience a compound annual growth rate (CAGR) of 7.3%. Key factors fueling this growth during the historical period include a surge in psoriasis cases, growing co-morbidities prevalence, encouraging reimbursement policies, a rise in alcohol and tobacco usage, along with the advent of telemedicine.

How fast Is the chronic plaque psoriasis market expected to grow, and what’s its future value?

The market for chronic plaque psoriasis is anticipated to experience significant expansion over the coming years. With a predicted compound annual growth rate (CAGR) of 7.1%, it’s estimated to reach a market size of $29.33 billion by 2029. Several factors contribute to this growth, including a global rise in the prevalence of cpp, an increase in autoimmune diseases, expanding healthcare budgets, an aging population, and a growing demand for efficacious treatments. Key trends to watch for in this forecast period are developments in biologic treatments, the inception of oral small molecule inhibitors, the integration of digital health, personalized medicine, and the introduction of biosimilars.

Get your chronic plaque psoriasis market report here!

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

What are the leading drivers of growth in the chronic plaque psoriasis market?

An uptick in immune system dysfunction cases is anticipated to spur the chronic plaque psoriasis market’s advancement. Immune system dysfunction is a state in which the immune system’s operation is compromised, leading to heightened risk of infections, autoimmune diseases, and cancer. This increase is attributed to elements such as hereditary propensity, environmental factors, poor nutrition, chronic stress, and a surge in autoimmune diseases and infections, including HIV. Treatment for chronic plaque psoriasis is necessary to balance immune system dysfunction, which erroneously triggers an excessive production of skin cells, causing inflammation and plaque creation. As an illustration, in December 2022, the National Psoriasis Foundation, a nonprofit organization based in the US, documented that psoriasis affects more than 8 million Americans. Worldwide, this condition affects 125 million individuals, representing 2 to 3% of the total global population. Consequently, the escalating instances of immune system dysfunction are instrumental in the growth surge of the chronic plaque psoriasis market.

What are the key segments defining the chronic plaque psoriasis market?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Who are the key players steering the development of the chronic plaque psoriasis market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

What are the key trends shaping the future of the chronic plaque psoriasis market?

Major companies operating in the chronic plaque psoriasis market are focusing on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to gain advancement in the treatment of chronic plaque psoriasis. IL-17A and IL-17F inhibitors are targeted biologic therapies that block interleukin-17A and interleukin-17F, pro-inflammatory cytokines involved in the immune response, to reduce inflammation in autoimmune diseases like chronic plaque psoriasis. For instance, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Bimekizumab is the first approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines involved in inflammatory processes. Its approval was based on evidence from three Phase 3 multicenter trials—BE READY, BE VIVID, and BE SURE—which collectively assessed its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

Which regions are most influential in expanding the chronic plaque psoriasis market?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Psoriasis Global Market Report 2025

https://thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Global G-CSF (Granulocyte Colony Stimulating Factors) Opportunities And Strategies Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Chronic Plaque Psoriasis Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The market for chronic plaque psoriasis has seen robust growth in the past few years. Its size is projected to increase from $20.79 billion in 2024 to $22.32 billion in 2025, signifying a compound annual growth rate (CAGR) of 7.3%. This expansion during the historic era is credited to the escalating incidence of psoriasis and associated co-morbidities, favorable insurance reimbursement strategies, growing alcohol and smoking use, and the emergence of telemedicine.

In the coming years, the market size for chronic plaque psoriasis is projected to experience a substantial increase, with a valuation of $29.33 billion in 2029, reflecting a compound annual growth rate (CAGR) of 7.1%. The growth within this forecast period is likely due to the global rising or falling prevalence of cpp, an increase in autoimmune diseases, expansion in healthcare budgets, aging demographic, and a growing demand for effective treatments. The period is also expected to see significant trends such as advancements in biologic treatments, oral small molecule inhibitors, digital health integration, personalized medicine, and the advent of biosimilars.

What Drivers Are Shaping the Growth of the Chronic Plaque Psoriasis Market?

Growth in the chronic plaque psoriasis market is projected to be fueled by the uptick in immune system dysfunction cases. When the immune system is ineffective, it is referred to as immune system dysfunction, leading to heightened vulnerability to infections, autoimmune diseases, and cancer. Factors such as genetic predisposition, environmental influences, malnutrition, chronic stress, and a surge in infections like HIV and autoimmune diseases are driving the increase in immune system dysfunction cases. Chronic plaque psoriasis treatment is vital to control immune system dysfunction because the immune system unintentionally triggers excessive skin cell production, resulting in inflammation and plaque formation. For instance, in December 2022, the National Psoriasis Foundation, a nonprofit organization based in the US, stated that psoriasis impacts over 8 million Americans. Worldwide, 125 million people are affected by this condition, representing 2 to 3% of the global population. Consequently, the rise in incidents of immune system dysfunction is propelling the chronic plaque psoriasis market’s growth.

Get Your Free Sample of the Global Chronic Plaque Psoriasis Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Who Are the Influential Players Reshaping the Chronic Plaque Psoriasis Market Landscape?

Major companies operating in the chronic plaque psoriasis market are:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

• Bristol-Myers Squibb Company_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the Chronic Plaque Psoriasis Market?

Leading enterprises in the chronic plaque psoriasis market are prioritizing the development of novel therapies, such as IL-17A and IL-17F inhibitors, to achieve progress in treating chronic plaque psoriasis. These inhibitors are specialized biologic treatments that suppress interleukin-17A and interleukin-17F, substances that trigger inflammatory responses in the immune system, aiming to decrease inflammation in autoimmune conditions such as chronic plaque psoriasis. As an example, in October 2023, UCB S.A., a biopharmaceutical firm from Belgium, publicized that the U.S. Food and Drug Administration (FDA) approved its medication BIMZELX (bimekizumab-bkzx) for adult patients suffering from moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy. Bimekizumab is the pioneering medication given approval for psoriasis with the specific purpose to target and hinder interleukin 17A (IL-17A) and interleukin 17F (IL-17F), both crucial elements in inflammatory occurrences. Its endorsement comes from gathered data from three Phase 3 multicenter studies—BE READY, BE VIVID, and BE SURE—these studies evaluated its safety and effectiveness in 1,480 patients with moderate to severe plaque psoriasis.

Get Instant Access to the Global Chronic Plaque Psoriasis Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Key Segments Stand Out in Understanding the Composition of the Chronic Plaque Psoriasis Market?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Which Geographic Locations Are Critical to the Growth of the Chronic Plaque Psoriasis Market?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Chronic Plaque Psoriasis Market?

Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface.

Browse Through More Similar Reports By The Business Research Company:

Psoriasis Global Market Report 2025

https://thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Global G-CSF (Granulocyte Colony Stimulating Factors) Opportunities And Strategies Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: